Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Dec 3, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a protein called interleukin-6 (IL-6) affects the way glucagon, a hormone that helps control blood sugar levels, works in the body. Specifically, researchers want to find out if IL-6 changes how glucagon lowers the amount of amino acids (the building blocks of proteins) in the blood. To do this, they will compare the effects of a normal saline solution with a medication that blocks the IL-6 receptor.
Participants in the study will be healthy adults aged 18 to 50 with a body mass index (BMI) between 18.5 and 25, and they should have had a stable weight for the past six months. During the study, participants will first receive an infusion of either saline or the IL-6 blocker. After three weeks, they will return for another visit where they will receive infusions of hormones and amino acids to simulate different body conditions, and their blood will be tested multiple times to see how these substances are processed. It's important to note that certain health conditions, recent drug use, or pregnancy can make someone ineligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Age 18 to 50 years
- • BMI 18.5 - 25 kg/m2
- • Stable body weight in the past 6 months before study initiation
- • Women should be anovulatory on non-cyclic hormone replacement or hormonal contraception
- Exclusion criteria:
- • Previous medical history for any chronic condition in the last three months, active disease or abnormal physical examination as verified by a qualified physician
- • Body weight unstable in the past 6 months
- • Use of tobacco/nicotine
- • Alcohol consumption \>30g/day
- • Participation in an investigational drug trial within the past two months
- • Current intake of any drugs (prescribed, over the counter or recreational)
- • Known allergy to tocilizumab
- • Pregnant or lactating women,
- • Inability or unwillingness to provide informed consent
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Bs, Switzerland
Patients applied
Trial Officials
Beckey Trinh, MD, PhD
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported